Antheia Raises Additional $24 Million to Complete Series C Financing, Bringing Total Funds Raised to More than $175 Million Over Past Year
Advanced biosynthesis company will accelerate commercialization of critical pharmaceutical ingredients and establish U.S. manufacturing operations Menlo Park, Calif., January 27, 2026 – Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has completed a second close of its Series C financing, raising an additional $24 million. Combined with additional available capital and non-dilutive funding, including multiple project agreements with the U.S. […]